Becker Capital Management Inc. Lowers Holdings in UnitedHealth Group (UNH)

Becker Capital Management Inc. trimmed its stake in UnitedHealth Group (NYSE:UNH) by 12.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,782 shares of the healthcare conglomerate’s stock after selling 670 shares during the period. Becker Capital Management Inc.’s holdings in UnitedHealth Group were worth $1,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the business. Aevitas Wealth Management Inc. purchased a new stake in shares of UnitedHealth Group in the 4th quarter worth approximately $102,000. Exane Derivatives lifted its position in shares of UnitedHealth Group by 15,333.3% in the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock worth $102,000 after purchasing an additional 460 shares during the period. Pathstone Family Office LLC purchased a new stake in shares of UnitedHealth Group in the 4th quarter worth approximately $129,000. Trustcore Financial Services LLC purchased a new stake in shares of UnitedHealth Group in the 4th quarter worth approximately $133,000. Finally, Baystate Wealth Management LLC lifted its position in shares of UnitedHealth Group by 64.9% in the 4th quarter. Baystate Wealth Management LLC now owns 762 shares of the healthcare conglomerate’s stock worth $186,000 after purchasing an additional 300 shares during the period. 85.10% of the stock is owned by institutional investors.

NYSE UNH opened at $247.90 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market cap of $235.09 billion, a P/E ratio of 24.62, a PEG ratio of 1.41 and a beta of 0.75. UnitedHealth Group has a 52 week low of $172.60 and a 52 week high of $250.79.

UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.91 by $0.13. UnitedHealth Group had a net margin of 5.41% and a return on equity of 22.06%. The business had revenue of $55.19 billion for the quarter, compared to analyst estimates of $54.90 billion. During the same quarter in the prior year, the business posted $2.37 EPS. UnitedHealth Group’s revenue for the quarter was up 13.3% compared to the same quarter last year. research analysts forecast that UnitedHealth Group will post 12.61 earnings per share for the current fiscal year.

In other UnitedHealth Group news, Director Richard T. Burke sold 10,400 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $229.87, for a total transaction of $2,390,648.00. Following the transaction, the director now owns 1,781,657 shares in the company, valued at approximately $409,549,494.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard T. Burke sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 23rd. The shares were sold at an average price of $234.20, for a total transaction of $3,513,000.00. Following the transaction, the director now owns 1,761,533 shares in the company, valued at approximately $412,551,028.60. The disclosure for this sale can be found here. Insiders have sold a total of 72,019 shares of company stock worth $16,550,733 in the last 90 days. 0.87% of the stock is currently owned by company insiders.

Several equities research analysts have recently weighed in on the stock. ValuEngine raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of UnitedHealth Group from a “sell” rating to a “hold” rating in a research report on Thursday, April 19th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $270.00 price target on shares of UnitedHealth Group in a research report on Wednesday, April 18th. Credit Suisse Group upped their price target on shares of UnitedHealth Group from $260.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 18th. Finally, Oppenheimer upped their price target on shares of UnitedHealth Group from $260.00 to $276.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 18th. Two investment analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the stock. UnitedHealth Group presently has a consensus rating of “Buy” and a consensus price target of $253.70.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group (NYSE:UNH).

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply